Team:UCLA/Super Soldier Bacteria

Introduction

Antibiotic resistance is a renowned and pressing global health concern. In more recent times, there has been stagnation in discovering new classes of antibiotics, particularly for gram-negative bacteria. Throughout the mid-1900s, scientists were rapidly discovering the current major classes of antibiotics using the Waksman platform, which entailed systematically screening soil and fungal microbes for growth inhibition. However, the recurring problem of rediscovery and failure of subsequent high-throughput biochemical assays led many pharmaceutical companies to abandon their antibiotic development programs. Current antibiotics are generally broad-spectrum, acting against symbiotic gut flora in addition to pathogenic invaders. Therefore, specificity has recently become a target in modern antibiotic development in order to bypass challenges of both rediscovery and indiscriminate killing.

The core of antibiotic development lies in targeting a molecule or pathway essential for bacterial survival. Bacteria themselves have already developed several mechanisms to both communicate and compete with other bacterial strains occupying similar niches, which can be exploited for the creation of new antibiotic drugs. While some systems rely on secreted signaling molecules, direct cell-to-cell contact is also used to mediate intercellular interactions. Contact-dependent growth inhibition (CDI) is one such system that allows CDI+ bacterial strains to outcompete closely related CDI− siblings by synthesizing and translocating a toxin through the membrane of strains expressing the appropriate receptor. The CDI system is common in many strains of pathogenic gram-negative bacteria, such as Yersinia pseudotuberculosis and uropathogenic strains of Escherichia coli, making it a potentially suitable target for future antibiotics.

This type of growth inhibition was first seen in E. coli strain EC93, in which toxin delivery is mediated by the CdiA/CdiB two-partner secretion system and the outer membrane protein BamA, which is a conserved receptor among all strains of E. coli. EC93 is protected from its own toxin, located at the C-terminal region of CdiA (CdiA-CT), by the expression of a CdiI immunity protein that interacts directly with the toxin to neutralize its pore-forming capabilities. The CdiBAI cluster is common throughout most CDI+ strains, significantly varying only in CdiA-CT and CdiI sequences.

Our project focuses on the translocation of three different CDI systems from EC93 and Enterobacter aerogenes ATCC 13048 (containing two CDI loci) into one lab strain of E. coli to create a super-soldier organism that is able to selectively inhibit the growth of these strains. A lab strain containing CDIEC93, for instance, would be able to target all bacteria containing the corresponding receptor for CDIEC93, which would in this case be BamAEcoli. In order to target EC93 itself, however, we aim to switch CdiA-CTEC93 with a toxin from ATCC 13048 so that the immunity protein of EC93 does not prevent growth inhibition. It has previously been shown that CdiA-CT regions are modular, and systematically modularizing the toxin region using appropriate restriction sites is another goal of our project. While the CDI system in EC93 targets the BamAE. coli, the relevant receptors in other species of pathogens and even in other strains of E. coli is unknown. An additional facet to our project would be to find the receptors that each CDI system of ATCC 13048 targets by creating a transposon insertion library. Mutants that display a whole or partial CDI immunity phenotype will be sequenced to determine which genes have undergone transposon insertion, providing insight into which receptors may be targeted by ATCC 13048 CDI systems.